For GLUT1 deficiency syndrome (GLUT1-DS), a treatable metabolic encephalopathy characterized by complex movement disorders, drug-resistant epilepsy, and cognitive impairment, KDT is recognized as the gold standard treatment (9) and patients undergoing KDT are likely to achieve an optimal control of seizures (10). Here, SLC2A1 is linked to epilepsy.